Sex differences in response to miRNA‐34a therapy in mouse models of cardiac disease: identification of sex‐ disease‐ and treatment‐regulated miRNAs

摘要

Key points class="unordered" style="list-style-type:disc" id="tjp7368-list-0001">MicroRNA (miRNA)‐based therapies are in development for numerous diseases, including heart disease. Currently, very limited basic information is available on the regulation of specific miRNAs in male and female hearts in settings of disease. The identification of sex‐specific miRNA signatures has implications for translation into the clinic and suggests the need for customised therapy.In the present study, we found that a miRNA‐based treatment inhibiting miRNA‐34a (miR‐34a) was more effective in females in a setting of moderate dilated cardiomyopathy than in males. Furthermore, the treatment showed little benefit for either sex in a setting of more severe dilated cardiomyopathy associated with atrial fibrillation.The results highlight the importance of understanding the effect of miRNA‐based therapies in cardiac disease settings in males and females.